Fri, September 29, 2017
Thu, September 28, 2017
Wed, September 27, 2017
Tue, September 26, 2017
Mon, September 25, 2017
Fri, September 22, 2017
Thu, September 21, 2017
Wed, September 20, 2017
Tue, September 19, 2017
Mon, September 18, 2017
Fri, September 15, 2017
Thu, September 14, 2017
Wed, September 13, 2017
Tue, September 12, 2017
Mon, September 11, 2017
Fri, September 8, 2017
Thu, September 7, 2017
Wed, September 6, 2017
Tue, September 5, 2017
Fri, September 1, 2017
Thu, August 31, 2017
Wed, August 30, 2017

Kennen MacKay Initiated (ANAB) at Buy and Held Target at $40 on, Sep 15th, 2017


  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. -buy-and-held-target-at-40-on-sep-15th-2017.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Kennen MacKay of RBC Capital, Initiated "AnaptysBio, Inc." (ANAB) at Buy and Held Target at $40 on, Sep 15th, 2017.

Kennen has made no other calls on ANAB in the last 4 months.



There are 2 other peers that have a rating on ANAB. Out of the 2 peers that are also analyzing ANAB, 0 agree with Kennen's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Kennen


  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $38 on, Friday, August 25th, 2017
  • Neena Bitritto-Garg of "Baird" Initiated at Buy and Held Target at $36 on, Tuesday, July 11th, 2017

Publication Contributing Sources